Skip to main content
. Author manuscript; available in PMC: 2019 Nov 11.
Published in final edited form as: Diabetes Res Clin Pract. 2014 Oct 23;107(2):280–289. doi: 10.1016/j.diabres.2014.10.007

Table 2 –

The roles of DCCT-severe hypoglycemia and DCCT-A1C in atherosclerosis (entire cohort).

clinical factor of interest in model Risk ratio for an association with CAC ≥ 100 model 1a p-value Risk ratio for an association with CAC ≥ 100 model 2b p-value
DCCT-severe hypoglycemia rate 1.12 (0.99–1.29) 0.093 1.13 (0.97–1.32) 0.11
DCCT-AIC 1.21 (1.09–1.35) <0.001 1.21 (1.03–1.42) <0.05
a

Model 1: Adjusted for gender, baseline age; The p-value for group treatment when included in the model was 0.7.

b

Model 2: Adjusted for group treatment, systolic blood pressure, LDL-cholesterol, BMI, smoking, baseline clinical neuropathy, baseline diabetes duration, baseline hypoglycemia, scanning site, baseline retinopathy, and baseline-AER. p-value for group treatment was 0.71).